Eversana Intouch
NOVEMBER 9, 2023
Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. By 2018, that share had fallen by about half.
PM360
JULY 18, 2022
SPAG, which serves global biopharma companies, health trade associations, and health provider systems, is also one of the most awarded agencies in the region having been named Global New PR Agency in 2015, Asia-Pacific Healthcare Agency of Year (2017 & 2019) at Sabre awards, and Large Agency of the Year in 2021 & 2022 by E4M (IPRCCA).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 19, 2023
billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. Following his graduate studies, Dr Hoppin was an Alexander von Humboldt Fellow at the Research Center Jülich, Center for Electronics in Germany from 2003 to 2005.
PM360
NOVEMBER 12, 2024
From your work on the AstraMerck merger to your leadership at Alnylam, you’ve been in the biopharma industry for over 30 years. since 2007, and he previously held the position of chief operating officer when he first joined the company in 2003. Food and Drug Administration approval and launch of VELCADE® (bortezomib) in mid-2003.
Pharmaceutical Technology
AUGUST 26, 2008
“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. .”
Silver Line CRM
SEPTEMBER 24, 2020
VMS biopharma clients expect them to move quickly — and to do so, the company saw an opportunity to streamline processes, drive efficiencies, and make it more seamless for its team to work together. . Our custom system was built in 2003,” said Brochhagen.
European Pharmaceutical Review
DECEMBER 21, 2022
Org Process Res Dev 2020, 24, 10, 1996–2003. Biopharma successful in achieving climate-related goals, report finds … . Shores BT, Sieg PE, Nicosia AT, et al. Design of a Continuous Solvent Recovery System for End-to-End Integrated Continuous Manufacturing of Pharmaceuticals. EFPIA White Paper on Circular Economy, June 2020.
Expert insights. Personalized for you.
105 
Let's personalize your content